- In April 2023, Contipro a.s., a Czech biotechnology company specializing in hyaluronic acid production, announced the development of a new high-purity HA formulation designed for ophthalmic applications. This innovation aims to enhance the efficacy of eye drop solutions used in treating dry eye syndrome and post-surgical recovery, reflecting the company's commitment to advancing HA applications in specialized medical fields
- In March 2023, Bloomage Biotechnology Corporation Limited, a leading Chinese manufacturer of hyaluronic acid, expanded its production capacity by inaugurating a new manufacturing facility in Jinan, China. This expansion is intended to meet the growing global demand for HA in cosmetics, pharmaceuticals, and dietary supplements, reinforcing Bloomage's position in the international HA market
- In February 2023, Seikagaku Corporation, a Japanese pharmaceutical company, received regulatory approval in Japan for its new HA-based injectable treatment for knee osteoarthritis. The product, named HyLink, utilizes a novel cross-linking technology to provide longer-lasting relief from joint pain, marking a significant advancement in HA-based osteoarthritis therapies
- In January 2023, Anika Therapeutics, a U.S.-based company specializing in regenerative therapies, launched a new line of HA-based dermal fillers under the brand name Resilient HA. These fillers are designed to offer enhanced elasticity and longevity, catering to the increasing demand for non-surgical aesthetic treatments in the cosmetic industry.
- In December 2022, LG Chem, a South Korean chemical company, announced a strategic partnership with a European pharmaceutical firm to co-develop HA-based treatments for inflammatory skin diseases. This collaboration aims to leverage LG Chem's expertise in HA production and the partner's clinical development capabilities to address unmet needs in dermatological care
